Tag Archives: T-cell therapy

April, 2018

12 April
FDA Lifts Clinical Hold on US Studies of Bellicum’s BPX-501

HOUSTON, April 11, 2018 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the U.S. Food and Drug Administration has lifted the clinical hold on studies of BPX-501 in the U.S. The decision follows consultation with the FDA and agreement on amendments …
Share

4 January
Kite Pharma Submits IND Application for Next Generation TCR Therapy KITE-718

SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite Pharma, Inc. (Nasdaq:KITE) today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 trial of KITE-718, a T cell therapy engineered to express T cell receptors (TCRs) that target MAGE A3 …
Share

26 September
Adaptimmune and MD Anderson Partner to Advance Development of Immunotherapies for Multiple Cancers

PHILADELPHIA and HOUSTON, United States and OXFORD, United Kingdom, Sept. 26, 2016 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and The University of Texas MD Anderson Cancer Center announced today that they have entered into a multi-year strategic alliance designed to expedite …
Share

5 August
FDA Puts a Partial Clinical Hold on Adaptimmune’s Cancer Therapy Trial

PHILADELPHIA and OXFORD, United Kingdom, Aug. 03, 2016 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that it has received notice from the U.S. Food and Drug administration that a partial clinical hold has been placed on its planned pivotal …
Share

2 February
GSK and Adaptimmune Expand Immunotherapy Collaboration

GlaxoSmithKline plc (LSE/NYSE: GSK) and Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in the use of T-cell receptor (TCR) engineered T-cell therapy to treat cancer, today announced that the companies have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune’s lead clinical cancer programme, an affinity enhanced T-cell …
Share